October 18, 2007 NASD OTC-BB: MRDAF

Clinical Study Revealing Girth Reduction with Non-invasive Laser to be Presented at the NAASO Meeting

Results from a Louisiana State University study in which the LAPEX 2000 LipoLaser was used to reduce girth around study participants' waistlines is scheduled to be presented at the North American Association for the Study of Obesity (NAASO) Annual Scientific Meeting, Oct. 20, in New Orleans. Study leaders will reveal that within the study group the new LAPEX 2000 LipoLaser, manufactured by Meridian Co., Ltd., provided "significant girth loss that is sustained over repeated treatments". The forty study participants (both men and women between the ages of 18 and 65) experienced an average girth loss of one inch over the course of the study.

"We sincerely appreciate all the efforts of Dr. Frank Greenway and the entire study team at LSU for their efforts to prove the LAPEX 2000 LipoLaser is effective for its intended use," said Anna Brazier, President of Belgium Medical, Inc., the exclusive North American distributor for the LipoLaser. "This study was a significant part of our FDA submission for body contouring and girth reduction indications which, to our knowledge, will be the first laser in the entire aesthetics industry for this 100% non-invasive modality."

Brazier is currently awaiting a response from the FDA regarding a submission for the two new aesthetic indications. The LAPEX 2000 has already received clearance for sale and use in the United States for general hand and wrist pain associated with Carpal Tunnel Syndrome.

"Due to the uniqueness of our claims regarding how the device reduces fat within the body, we needed to address additional questions. We feel we have successfully fulfilled that obligation," said Brazier. "Based on our very recent CE clearance, which allows us to market the device for body contouring and girth reduction throughout the entire European Union, combined with our submission to FDA, we look forward to updating all our stakeholders with favorable information in the near future."

In related news, Meridian is currently reviewing proposals for the distribution of the LAPEX 2000 LipoLaser in France, Turkey, Dubai and Mexico.

The Company has hired Jay Hopkins, a sales and marketing professional with several years of experience in the aesthetics industry, to oversee the North American launch of the LAPEX 2000 LipoLaser once the new indications are approved. Most recently, Hopkins sold Class IV laser equipment from Iridex and Laserscope to the dermatology and plastic surgery market. Hopkins plans to conduct LipoLaser sales and marketing out of his Seattle, Washington-based offices.

More About: LAPEX 2000 LipoLaser

The LAPEX 2000 LipoLaser was designed to target the medical and aesthetic market, specifically to address body shaping/contouring, spot fat reduction. The LAPEX 2000 LipoLaser's non-invasive treatment is considered one of the most innovative methods to treat those stubborn areas of fat that do not respond to diet and exercise. The demand for this type of treatment is expected to grow rapidly, not only in the plastic surgery profession but in any clinical setting such as medi-spas and wellness centers that treat localized body fat deposits which may not have responded to diet and exercise.

More About: Meridian

Meridian is an established leader in the research/development, manufacturing and sales of advanced medical devices in the healthcare industry. With a dynamic research and development team, Meridian is at the forefront in the development of cutting edge medical technologies. The Company presently holds a total of 18 worldwide patents on its technology, and has received FDA clearance and Health Canada approval as well as other international regulatory approvals, for many of its products. Meridian has over 1500 clients including physicians, hospitals, clinics, healthcare professionals, and wellness centers in Korea, USA, Canada, China, Japan and Europe, and continues to successfully market its superior product line to a growing number of clients worldwide.

On Behalf of the Board of Directors,

Hyeon Seong Myeong, President

This press release may contain certain forward-looking information and statements concerning the company's operations, performance and financial condition. These statements are based upon a number of uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. This document is not intended to be and is not an advertisement for any securities of the Company.

Contacts:
Meridian Co., Ltd.
Peter Holeczek
Corporate Communications
1-866-736-3306
Website: https://MeridianMedical.ca